ReviewCells2026
Human Cytomegalovirus as a Therapeutic Target in Glioma Stem Cells.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glioblastoma is the most aggressive tumor among gliomas, and recurrence remains inevitable despite aggressive therapies. Resistance to existing treatment modalities is attributed in part to the presence of glioma stem cells, which comprise a distinct cell subpopulation that sustains cell renewal and tumor evasion through multiple mechanisms. Therapeutic strategies using herpesviruses have been evaluated following the discovery of differential human cytomegalovirus (HCMV) expression in glioblastoma tumor cells. The absence of expression in normal brain tissue led to multiple clinical trials demonstrating the potential clinical utility of targeted HCMV via herpesvirus-based oncolytic therapeutic strategies. This review provides a comprehensive overview of existing studies evaluating the expression and biological significance of HCMV within glioma stem cells. Targeting HCMV in this cellular compartment may disrupt the continuous cellular support and resilience of glioblastoma stem cells, thereby enhancing the efficacy of current treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.